Stopped: Sponsor decision, indication no longer under evaluation
The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The optimal regimen for renal allograft tolerance while minimizing chimeric transition syndrome
Timeframe: 24 months